This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages before signing in

Go to /pro/cpd-dashboard page

This page is worth 0.05 CPD credits. CPD dashboard

Go to /account/subscription-details page

This page is worth 0.05 CPD credits. Upgrade to Pro

Hydralazine

Last reviewed dd mmm yyyy. Last edited dd mmm yyyy

Authoring team

This is a drug used in the treatment of cardiac failure and hypertension.

Mode of action:

  • direct relaxing effect on vascular smooth muscle resulting in peripheral arteriolar dilatation

There is a fall in blood pressure and consequent reflex tachycardia as a result of the peripheral arteriolar dilatation caused by hydralazine. Thus, in the treatment of hypertension, a beta-adrenoreceptor blocker is also is used. There is little reflex tachycardia when this drug is used to treat cardiac failure because there is no significant change in blood pressure.

Pharmacokinetics:

  • t 1/2 - approximately 4 hours
  • metabolised - mainly by acetylation

Side effects:

  • palpitations, nausea, vomiting, tachycardia, postural hypotension
  • with dosages over 200 mg then there may be the development of a lupus-like syndrome or an arthropathy resembling rheumatoid arthritis. The lupus-like syndrome that may occur with the use of hydralazine is more commonly seen in patients with HLA DR4.

Related pages

Create an account to add page annotations

Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.